A Phase 3 interventional study of Lenalidomide and Chlorambucil in B-Cell Chronic Lymphocytic Leukemia, sponsored by Celgene. Completed at 165 sites in 27 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2019-07-09.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 5 under way, none of them phase 3. Lenalidomide · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell, this one has the largest enrollment of the 77 interventional ones that give a count, is one of 10 that started in 2009, is one of 3 in phase 3, and was the 29th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →1 of the 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 1 country. Recruiting first, the newest first:
Vitebsk Regional Clinical Cancer Centre · Sites in Belarus
Ages 18+
By country, each count listing its studies:
Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 55 · Phase 3 3
First in 2002; this study’s year is marked. 10 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 450 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 29 across the 77 interventional studies. Of the 65 that completed or were terminated, 41 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 78 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
25 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Bristol-Myers Squibb: 1 open now, 3 under way, none of them phase 3. Of 19 finished, 6 (32%) have results posted.
Among the 25 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Bristol-Myers Squibb, this one has the largest enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2009, is one of 3 in phase 3, and was the 7th registered.
Bristol-Myers Squibb’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 25 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety and efficacy of lenalidomide as a first line therapy in treating patients with B-cell Chronic Lymphocytic Leukemia. This study will compare the effects (good and bad) of lenalidomide with chlorambucil.
After notification from the US Food and Drug Administration (FDA) on 12 July 2013, Celgene agreed to discontinue the lenalidomide treatment for all patients due to an imbalance in the number of deaths in patients treated with lenalidomide versus patients treated with chlorambucil. No specific causality for this imbalance has been identified to date. Investigators were instructed to immediately discontinue all participants from experimental lenalidomide treatment and inform their patients accordingly. Participants on the Chlorambucil arm may continue up to 12 months (13 cycles) with the last participant completing in March 2014. All randomized participants will continue to be followed for overall survival and secondary primary malignancies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Prior history of , other than CLL, unless the subject has been free of the disease for ≥3 years. Exceptions include the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 - Lenalidomide
Drug: Lenalidomide
2- Chlorambucil
Drug: Chlorambucil
For patients with normal renal function (defined as CrCl ≥ 60 mL/min), 5 mg once daily on Days 1 through 28 of the first 28-day cycle, 10 mg once daily on Days 1 through 28 starting at the second cycle, 15 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first. For patients with moderate renal impairment (defined as CrCl ≥ 30 to \< 60 mL/min), 2.5 mg once daily on Days 1 through 28 of the first 28-day cycle, 5 mg once daily on Days 1 through 28 starting at the second cycle, 7.5 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first.
Also known as: Revlimid
Patients assigned to the chlorambucil arm will receive oral chlorambucil tablets at 0.8 mg/kg on Days 1 and 15 of each 28-day cycle for a total duration of 12 months (approximately 13 cycles).
Also known as: Leukeran
Kaplan-Meier Estimate of Progression Free Survival (PFS)
Progression-free survival was defined as the time from randomization to the first documented progression confirmed per investigator's assessment or death due to any cause on study, whichever occurred first. The progression date was assigned to the earliest time when any progression was observed without prior missing assessments. If withdrawal of consent or lost to follow-up occurred before documented progression or death, then these observations were censored at the date when the last complete tumor assessments determined a lack of progression
Time frame: From first dose of study drug to date of data cut-off of 18 Feb 2013; up to approximately 39 months
Kaplan-Meier Estimate of Progression Free Survival (PFS) With a Later Cut-off Date of 14 March 2014
Progression-free survival was defined as the time from randomization to the first documented progression confirmed per investigator's assessment or death due to any cause on study, whichever occurred first. Progressive disease included lymphadenopathy, an appearance of any new lesion such as enlarged lymph nodes (\> 1.5 cm), splenomegaly, hepatomegaly or other organ infiltrates, an increase by 50% or more in greatest determined diameter of any previous site or an increase by 50% or more in the sum of the product of diameters of multiple nodes. The progression date was assigned to the earliest time when any progression was observed without prior missing assessments. If withdrawal of consent or lost to follow-up occurred before documented progression or death, then these observations were censored at the date when the last complete tumor assessments determined a lack of progression.
Time frame: From randomization to data cut off date of 31 March 2014; median follow up time for all participants was 12.6 months
Number of Participants With Adverse Events (AEs)
AEs = any noxious, unintended, or untoward medical occurrence that may appear or worsen during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, regardless of cause. Serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs were graded based upon the participants symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0); AEs were evaluated for severity according to the following scale: Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening; Grade 5 = Death
Time frame: From randomization up to data cut-off of 18 Feb 2013; Up to approximately 39 months; maximum duration of exposure for Lenalidomide was 1086 days and 406 days for Chlorambucil
Number of Participants With Adverse Events With a Later Cut-off Date of 31 March 2014
AEs = any noxious, unintended, or untoward medical occurrence that may appear or worsen during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, regardless of cause. Serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs were graded based upon the participants symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0); AEs were evaluated for severity according to the following scale: Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening; Grade 5 = Death
Time frame: From randomization to the data cut-off date of 31 March 2014; Up to 53 months; maximum duration of exposure for Lenalidomide was 1140 days and 406 days for Chlorambucil
Percentage of Participants With the Best Overall Response Based on the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Guidelines
A best overall response rate is a CR, CRi, nPR or PR and is defined as: Complete Remission (CR): * No lymphadenopathy * No hepatomegaly or splenomegaly * Absence of constitutional symptoms * Polymorphonuclear leukocytes ≥ 1500/ul * No circulating clonal B-lymphocytes * Platelets \> 100,000/ul * Hemoglobin \> 11.0 g/dl * Normocellular \<30% lymphocytes, no B-lymphoid nodules; Incomplete Clinical Response (CRi): • CR without bone marrow biopsy confirmation. Nodular Partial Response (nPR): • CR with the presence of residual clonal nodules. Partial Response (PR) requires: * ≥ 50% decrease in peripheral blood lymphocyte count * ≥ 50% reduction in lymphadenopathy * ≥ 50% reduction in size of liver and/or spleen * 1 or more of the following: * Polymorphonuclear leukocytes ≥ 1500/ul * Platelets \>100,000/ul
Time frame: Up to data cut-off date of 18 Feb 2013; approximately 39 months
Percentage of Participants With a Best Overall Response Based on IWCLL Guidelines With a Later Cut-off Date of 31 March 2014
A best overall response rate is a CR, CRi, nPR or PR and is defined as: Complete Remission (CR): * No lymphadenopathy * No hepatomegaly or splenomegaly * Absence of constitutional symptoms * Polymorphonuclear leukocytes ≥ 1500/ul * No circulating clonal B-lymphocytes * Platelets \> 100,000/ul * Hemoglobin \> 11.0 g/dl * Normocellular \<30% lymphocytes, no B-lymphoid nodules; Incomplete Clinical Response (CRi): • CR without bone marrow biopsy confirmation. Nodular Partial Response: • CR with the presence of residual clonal nodules. Partial Response requires: * ≥ 50% decrease in peripheral blood lymphocyte count * ≥ 50% reduction in lymphadenopathy * ≥ 50% reduction in size of liver and/or spleen * 1 or more of the following: * Polymorphonuclear leukocytes ≥ 1500/ul * Platelets \>100,000/ul
Time frame: Up to data cut-off of 31 March 2014; approximately 53 months
Kaplan-Meier Estimate for Duration of Response
Duration of response was defined as the time from first nPR, PR, CRi, or CR to PD. Duration of response was censored at the last date that the patient was known to be progression-free for: 1) participants who had not progressed at the time of analysis; 2) participants who had withdrawn consent or were lost to follow-up prior to documentation of progression
Time frame: Up to data cut-off of 18 Feb 2013; up to approximately 39 months
Kaplan-Meier Estimate for Duration of Response With a Later Cut-off Date of 31 March 2014
Duration of response was defined as the time from first nPR, PR, CRi, or CR to PD. Duration of response was censored at the last date that the patient was known to be progression-free for: 1) patients who had not progressed at the time of analysis; 2) patients who had withdrawn consent or were lost to follow-up prior to documentation of progression
Time frame: Up to data cut-off of 31 March 2014; up to approximately 53 months
Time to Response
Time to response was calculated as the time from randomization to the first nPR, PR, CRi or CR based on IWCLL guidelines
Time frame: Up to data cut-off of 18 Feb 2013; up to approximately 39 months
Time to Response for a Later Cut-off Date of 31 March 2014
Time to response was calculated as the time from randomization to the first nPR, PR, CRi or CR based on IWCLL guidelines
Time frame: Up to data cut-off of 31 March 2014; up to approximately 53 months
Kaplan Meier Estimate of Overall Survival
Overall Survival is defined as the time between randomization and death from any cause.
Time frame: Up to data cut off of 31 March 2014; median follow-up for all participants was 18.8 months
Kaplan Meier Estimate for Overall Survival at the Final Analysis
Overall Survival is defined as the time between randomization and death from any cause. Overall survival was censored at the last date that the subject was known to be alive for participants who were alive as of the data cutoff date and for participants who were lost to follow-up before death was documented.
Time frame: Up to the last patient last visit date of 19 May 2018; median follow-up for all participants was 46.7 months
Functional Assessment of Cancer Therapy-General to Create the FACT-Leukemia (FACT-Leu) Quality of Life Instrument
The FACT-Leu scale is a valid, reliable, and efficient measure of leukemia-specific health-related quality of life for acute and chronic disease. The FACT-Leu is described as including 27 items that assess 17 physical symptoms (fevers, bleeding, general pain, stomach pain, chills, night sweats, bruising, lymph node swelling, weakness, tiredness, weight loss, appetite, shortness of breath, functional ability, diarrhea, concentration, and mouth sores) and 10 emotional/social concerns (frustration with activity limitation, discouraged by illness, future planning, uncertainty, worry about illness, emotional lability, isolation, infertility concern, family worry, and worry about infections).
Time frame: Day 1 and once every 8 weeks
Euro Quality of Life Five Dimension (EQ-5D) Questionnaire
The standardized extended version of EQ-5D was designed for the collection of health state values using a visual analogue scale (VAS) rating scale - a vertical 20 cm visual analogue scale with the end points labeled best imaginable health state at the top and worst imaginable health state at the bottom having numeric values of 100 and 0 respectively. The participant is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions.
Time frame: Day 1 and once every 8 weeks
Number of Participants and Types of Subsequent Anti-cancer Therapies Received Post Treatment
Subsequent anti-cancer therapies administered to participants following the discontinuation of study drug (either Lenalidomide or Chlorambucil)
Time frame: Up to the last patient last visit date of 19 May 2018; median follow-up for all participants was 46.7 months
Number of Participants Deaths During the Treatment and Survival Follow-Up Phase
The number of study participants deaths during the treatment and follow-up phase
Time frame: From the first dose of study drug up to the last patient last visit date of 19 May 2018; median follow-up for all participants was 46.7 months
118 sites randomized participants in Austria, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, Columbia, Croatia, Czech Republic, Denmark, Hungary, Israel, Italy, the Netherlands, New Zealand, Poland, Portugal, Romania, Russia, South Africa, Slovakia, Spain, Serbia, the United Kingdom, and the United States of America
| Milestone | Lenalidomide | Chlorambucil |
|---|---|---|
| Started | 225 | 225 |
| Safety population | 224 | 223 |
| Completed | 0 | 1 |
| Not completed | 225 | 224 |
| Withdrew: Adverse event | 63 | 35 |
| Withdrew: Pd without histologic change | 27 | 23 |
| Withdrew: Pd with histologic change | 0 | 2 |
| Withdrew: Withdrawal by subject | 7 | 5 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Death | 9 | 3 |
| Withdrew: Protocol violation | 2 | 2 |
| Withdrew: Completed 13 cycles of treatment | 0 | 118 |
| Withdrew: Other | 114 | 32 |
| Withdrew: Untreated before cycle 1 | 1 | 2 |
Progression-free survival was defined as the time from randomization to the first documented progression confirmed per investigator's assessment or death due to any cause on study, whichever occurred first. The progression date was assigned to the earliest time when any progression was observed without prior missing assessments. If withdrawal of consent or lost to follow-up occurred before documented progression or death, then these observations were censored at the date when the last complete tumor assessments determined a lack of progression
| months | Lenalidomide | Chlorambucil |
|---|---|---|
| Kaplan-Meier Estimate of Progression Free Survival (PFS) | 30.8 (18.7 to NA) | 23.0 (19.3 to 29.2) |
Progression-free survival was defined as the time from randomization to the first documented progression confirmed per investigator's assessment or death due to any cause on study, whichever occurred first. Progressive disease included lymphadenopathy, an appearance of any new lesion such as enlarged lymph nodes (\> 1.5 cm), splenomegaly, hepatomegaly or other organ infiltrates, an increase by 50% or more in greatest determined diameter of any previous site or an increase by 50% or more in the sum of the product of diameters of multiple nodes. The progression date was assigned to the earliest time when any progression was observed without prior missing assessments. If withdrawal of consent or lost to follow-up occurred before documented progression or death, then these observations were censored at the date when the last complete tumor assessments determined a lack of progression.
| months | Lenalidomide | Chlorambucil |
|---|---|---|
| Kaplan-Meier Estimate of Progression Free Survival (PFS) With a Later Cut-off Date of 14 March 2014 | 30.8 (18.7 to NA) | 21.4 (19.3 to 25.1) |
AEs = any noxious, unintended, or untoward medical occurrence that may appear or worsen during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, regardless of cause. Serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs were graded based upon the participants symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0); AEs were evaluated for severity according to the following scale: Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening; Grade 5 = Death
| participants | Lenalidomide | Chlorambucil |
|---|---|---|
| ≥ 1 TEAE | 202 | 186 |
| ≥ 1 TEAE related to study drug | 183 | 139 |
| ≥ 1 NCI CTC Grade 3-4 TEAE | 173 | 117 |
| Grade 3-4 adverse event related to any study drug | 143 | 82 |
| ≥ 1 NCI CTC Grade 5 TEAE | 21 | 9 |
| ≥ Grade 5 adverse event related to any study drug | 6 | 1 |
| ≥ 1 Serious TEAE | 129 | 76 |
| ≥ 1 Serious TEAE related to any study drug | 95 | 46 |
| ≥1 TEAE leading to stopping either study drug | 61 | 34 |
| ≥1 Related TEAE leading to stopping either drug | 39 | 19 |
AEs = any noxious, unintended, or untoward medical occurrence that may appear or worsen during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, regardless of cause. Serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs were graded based upon the participants symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0); AEs were evaluated for severity according to the following scale: Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening; Grade 5 = Death
| participants | Lenalidomide | Chlorambucil |
|---|---|---|
| ≥ 1 TEAE | 216 | 202 |
| ≥ 1 TEAE related to study drug | 194 | 155 |
| ≥ 1 NCI CTC Grade 3-4 TEAE | 188 | 131 |
| Grade 3-4 adverse event related to any study drug | 157 | 90 |
| ≥ 1 NCI CTC Grade 5 TEAE | 21 | 11 |
| ≥ Grade 5 adverse event related to any study drug | 6 | 1 |
| ≥ 1 Serious TEAE | 148 | 90 |
| ≥ 1 Serious TEAE related to any study drug | 107 | 53 |
| ≥1 TEAE leading to stopping either study drug | 70 | 42 |
| ≥1 Related TEAE leading to stopping either drug | 46 | 23 |
A best overall response rate is a CR, CRi, nPR or PR and is defined as: Complete Remission (CR): * No lymphadenopathy * No hepatomegaly or splenomegaly * Absence of constitutional symptoms * Polymorphonuclear leukocytes ≥ 1500/ul * No circulating clonal B-lymphocytes * Platelets \> 100,000/ul * Hemoglobin \> 11.0 g/dl * Normocellular \<30% lymphocytes, no B-lymphoid nodules; Incomplete Clinical Response (CRi): • CR without bone marrow biopsy confirmation. Nodular Partial Response (nPR): • CR with the presence of residual clonal nodules. Partial Response (PR) requires: * ≥ 50% decrease in peripheral blood lymphocyte count * ≥ 50% reduction in lymphadenopathy * ≥ 50% reduction in size of liver and/or spleen * 1 or more of the following: * Polymorphonuclear leukocytes ≥ 1500/ul * Platelets \>100,000/ul
| percentage of participants | Lenalidomide | Chlorambucil |
|---|---|---|
| Percentage of Participants With the Best Overall Response Based on the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Guidelines | 51.9 | 62.3 |
A best overall response rate is a CR, CRi, nPR or PR and is defined as: Complete Remission (CR): * No lymphadenopathy * No hepatomegaly or splenomegaly * Absence of constitutional symptoms * Polymorphonuclear leukocytes ≥ 1500/ul * No circulating clonal B-lymphocytes * Platelets \> 100,000/ul * Hemoglobin \> 11.0 g/dl * Normocellular \<30% lymphocytes, no B-lymphoid nodules; Incomplete Clinical Response (CRi): • CR without bone marrow biopsy confirmation. Nodular Partial Response: • CR with the presence of residual clonal nodules. Partial Response requires: * ≥ 50% decrease in peripheral blood lymphocyte count * ≥ 50% reduction in lymphadenopathy * ≥ 50% reduction in size of liver and/or spleen * 1 or more of the following: * Polymorphonuclear leukocytes ≥ 1500/ul * Platelets \>100,000/ul
| percentage of participants with response | Lenalidomide | Chlorambucil |
|---|---|---|
| Percentage of Participants With a Best Overall Response Based on IWCLL Guidelines With a Later Cut-off Date of 31 March 2014 | 60.9 | 70.2 |
Duration of response was defined as the time from first nPR, PR, CRi, or CR to PD. Duration of response was censored at the last date that the patient was known to be progression-free for: 1) participants who had not progressed at the time of analysis; 2) participants who had withdrawn consent or were lost to follow-up prior to documentation of progression
| weeks | Lenalidomide | Chlorambucil |
|---|---|---|
| Kaplan-Meier Estimate for Duration of Response | NA (131.1 to NA) | 105.3 (77.4 to 123.7) |
Duration of response was defined as the time from first nPR, PR, CRi, or CR to PD. Duration of response was censored at the last date that the patient was known to be progression-free for: 1) patients who had not progressed at the time of analysis; 2) patients who had withdrawn consent or were lost to follow-up prior to documentation of progression
| weeks | Lenalidomide | Chlorambucil |
|---|---|---|
| Kaplan-Meier Estimate for Duration of Response With a Later Cut-off Date of 31 March 2014 | NA (149.4 to NA) | 87.1 (77.1 to 108.7) |
Time to response was calculated as the time from randomization to the first nPR, PR, CRi or CR based on IWCLL guidelines
| weeks | Lenalidomide | Chlorambucil |
|---|---|---|
| Time to Response | 8.6 (3.7 to 104.3) | 8.1 (3.7 to 52.7) |
Time to response was calculated as the time from randomization to the first nPR, PR, CRi or CR based on IWCLL guidelines
| weeks | Lenalidomide | Chlorambucil |
|---|---|---|
| Time to Response for a Later Cut-off Date of 31 March 2014 | 10.4 (3.7 to 136.1) | 8.1 (3.7 to 68.7) |
Overall Survival is defined as the time between randomization and death from any cause.
| Months | Lenalidomide | Chlorambucil |
|---|---|---|
| Kaplan Meier Estimate of Overall Survival | NA (NA to NA) | 44.0 (37.3 to NA) |
Overall Survival is defined as the time between randomization and death from any cause. Overall survival was censored at the last date that the subject was known to be alive for participants who were alive as of the data cutoff date and for participants who were lost to follow-up before death was documented.
| Months | Lenalidomide | Chlorambucil |
|---|---|---|
| Kaplan Meier Estimate for Overall Survival at the Final Analysis | 74.3 (58.5 to 84.4) | 70.5 (57.1 to NA) |
The FACT-Leu scale is a valid, reliable, and efficient measure of leukemia-specific health-related quality of life for acute and chronic disease. The FACT-Leu is described as including 27 items that assess 17 physical symptoms (fevers, bleeding, general pain, stomach pain, chills, night sweats, bruising, lymph node swelling, weakness, tiredness, weight loss, appetite, shortness of breath, functional ability, diarrhea, concentration, and mouth sores) and 10 emotional/social concerns (frustration with activity limitation, discouraged by illness, future planning, uncertainty, worry about illness, emotional lability, isolation, infertility concern, family worry, and worry about infections).
No measurements were reported for this outcome.
The standardized extended version of EQ-5D was designed for the collection of health state values using a visual analogue scale (VAS) rating scale - a vertical 20 cm visual analogue scale with the end points labeled best imaginable health state at the top and worst imaginable health state at the bottom having numeric values of 100 and 0 respectively. The participant is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions.
No measurements were reported for this outcome.
Subsequent anti-cancer therapies administered to participants following the discontinuation of study drug (either Lenalidomide or Chlorambucil)
| participants | Lenalidomide | Chlorambucil |
|---|---|---|
| Participants receiving additional CLL therapy | 125 | 120 |
| Participants receiving alkylating agents | 107 | 106 |
| Participants receiving antineoplastic aents | 93 | 86 |
| Participants receiving antimetabolites | 34 | 24 |
| Participants receiving corticosteroids | 27 | 16 |
| Participants receiving plant alkaloids | 22 | 11 |
| Participants receiving cytotoxic antibiotics | 10 | 3 |
| Participants receiving immunosuppressants | 3 | 2 |
| Participants receiving therapeutic products | 4 | 3 |
| Participants receiving other unspecified products | 0 | 2 |
| Antihistamine For Systemic Use | 1 | 1 |
| Drugs for Peptic ulcer and Gastric Reflex | 1 | 0 |
| Immunoglobulins | 1 | 2 |
| Other Analgesics and Antipyretics | 1 | 1 |
| Specific Antirheumatic Agents | 1 | 0 |
| Antiemetics and Antinauseants | 0 | 1 |
| Corticosteriods for Systemic Use | 0 | 1 |
| Immunostimulants | 0 | 1 |
The number of study participants deaths during the treatment and follow-up phase
| Participants | Lenalidomide | Chlorambucil |
|---|---|---|
| Number of Participants Deaths During the Treatment and Survival Follow-Up Phase | 101 | 95 |
Collected over All AEs were recorded by the Investigator(s) from first dose of study drug to 30 days after the treatment discontinuation visit. The median treatment duration was 263 days for lenalidomide and 362 days for chlorambucil.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lenalidomide | 100/224 (44.6%) | 148/224 (66.1%) | 204/224 (91.1%) |
| Chlorambucil | 93/223 (41.7%) | 90/223 (40.4%) | 184/223 (82.5%) |
| Event | Lenalidomide | Chlorambucil |
|---|---|---|
| NEUTROPENIABlood and lymphatic system disorders | 54/224 | 33/223 |
| PNEUMONIAInfections and infestations | 24/224 | 6/223 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 19/224 | 13/223 |
| ANAEMIABlood and lymphatic system disorders | 18/224 | 10/223 |
| PYREXIAGeneral disorders | 10/224 | 6/223 |
| BASAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 5/224 | 8/223 |
| TUMOUR FLARENeoplasms benign, malignant and unspecified (incl cysts and polyps) | 8/224 | 0/223 |
| SQUAMOUS CELL CARCINOMA OF SKINNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/224 | 7/223 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 7/224 | 3/223 |
| AUTOIMMUNE HAEMOLYTIC ANAEMIABlood and lymphatic system disorders | 3/224 | 4/223 |
| Event | Lenalidomide | Chlorambucil |
|---|---|---|
| NEUTROPENIABlood and lymphatic system disorders | 126/224 | 74/223 |
| TUMOUR FLARENeoplasms benign, malignant and unspecified (incl cysts and polyps) | 85/224 | 11/223 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 72/224 | 50/223 |
| ANAEMIABlood and lymphatic system disorders | 69/224 | 46/223 |
| DIARRHOEAGastrointestinal disorders | 66/224 | 32/223 |
| FATIGUEGeneral disorders | 66/224 | 53/223 |
| NAUSEAGastrointestinal disorders | 33/224 | 63/223 |
| OEDEMA PERIPHERALGeneral disorders | 43/224 | 16/223 |
| RASHSkin and subcutaneous tissue disorders | 41/224 | 19/223 |
| COUGHRespiratory, thoracic and mediastinal disorders | 38/224 | 21/223 |
The Intent-to-Treat (ITT) population was defined as all participants who were randomized, independent of whether they received study treatment or not.
| Age, Continuous(years) | Lenalidomide | Chlorambucil | Total |
|---|---|---|---|
| Mean | 73.0 ± 5.72 | 73.3 ± 5.72 | 73.1 ± 5.72 |
| Sex: Female, Male(Participants) | Lenalidomide | Chlorambucil | Total |
|---|---|---|---|
| Female | 93 | 83 | 176 |
| Male | 132 | 142 | 274 |
Showing the first 100 of 165 sites across 27 countries. Choose a country and city above to see the rest.
Ran from Oct 2009 to primary completion in Mar 2014, 53 months.
Results were first posted in Dec 2016, 2 years 8 months after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 53 months is close to that.
Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenalidomide
Leukemia, Lymphocytic, Chronic, B-Cell →